Bret M. Dickey

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Nuclear cataract resulting from an overdose of selenite was characterized by a five-fold increase in nuclear urea-soluble protein. The origin of this urea-soluble protein was examined by two-dimensional electrophoresis, immunoblotting with monospecific antisera against rat lens crystallins, and tryptic mapping. Cataractous urea-soluble protein was primarily(More)
“Reverse payment” patent settlements between brand and generic pharmaceutical manufacturers have received substantial scrutiny in recent years. While much has been written about the appropriate antitrust policy towards these settlements, the literature has paid little attention to the effect that changes in that policy might have on the incentives of(More)
Class action lawsuits offer a valuable and often viable mechanism for case management in private antitrust litigation when the number of potential plaintiffs is large. From a plaintiff’s perspective, the class certification mechanism is an effective and often efficient device that provides individuals, who might otherwise find it unaffordable, access to the(More)
This article demonstrates that in recent years, patent settlements between branded and generic manufacturers involving "reverse payments" from branded manufacturers to generic manufacturers have received close antitrust scrutiny, driven by concerns that such settlements harm consumers by delaying the entry of lower-priced generic drugs. The authors note(More)
  • 1